首页 | 本学科首页   官方微博 | 高级检索  
     


Changes in nationwide Medicare and Medicaid expenditures on lipid-lowering therapies after proprotein convertase/subtilisin type 9 inhibitor availability
Affiliation:1. The Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Md;2. Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Md;3. Department of Radiology and Neuroradiology, Charité, Berlin, Germany;4. Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark;5. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
Abstract:
Keywords:Lipid-lowering therapies  Pharmacoepidemiology  Statins  PCSK9 inhibitors  Medicare  Medicaid  Generic medications
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号